Japan’s MHLW Designates Three Drugs As Orphan Drugs
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labour and Welfare designated three drugs as orphan drugs, including two items for one drug for different indications. They are: Otsuka's tuberculoses drug OPC-67683 for preventing multi-drug resistance, currently in Phase II trials overseas; Celgene's CC-5013 (lenalidomide) for treating multiple myeloma in Phase I trials in Japan; and Celgene's CC-5013 for treating anemia caused by myelodysplastic syndrome. MHLW also reported that Chugai's Herceptin 60 and 150 injection is expected to be approved in March. (Click for more-Japanese language
You may also be interested in...
Busy Week For Japanese Firm Otsuka: Justice Dept. Settlement For Off-Label Abilify Marketing And New Partnership With MethylGene
Abilify developer Otsuka Pharmaceutical settled with the U.S. Department of Justice over charges the company illegally marketed the atypical antipsychotic off-label for pediatric and elderly populations in the U.S. from 2002 through 2005
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.